# A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

> **NCT00189241** · PHASE3 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 160 (—)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** imiquimod

## Key facts

- **NCT ID:** NCT00189241
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 160 (—)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189241, "A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00189241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*